ERBB2 and breast cancer: In the EU and the US, neratinib was approved as an adjuvant treatment for adults with early-stage, hormone-receptor-positive, HER2-overexpressed or amplified breast cancer and adults with less than one year from prior adjuvant trastuzumab-based therapy [71].